Clinical Trials Logo

Clinical Trial Summary

Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Motexafin gadolinium may increase the effectiveness of yttrium Y 90 ibritumomab tiuxetan by making the cancer cells more sensitive to the drug.

This phase I/II trial is studying the side effects and best dose of motexafin gadolinium when administered with rituximab and yttrium Y 90 ibritumomab tiuxetan and to see how well they work in treating patients with stage II, stage III, or stage IV relapsed or refractory non-Hodgkin's lymphoma.


Clinical Trial Description

This is a phase I, dose-escalation study of motexafin gadolinium followed by a phase II study. Patients are stratified according to extent of lymphomatous involvement (≤ 5% vs > 5 but ≤ 24% of cellular elements).

Cohorts of 3-6 patients in each stratum receive escalating doses of motexafin gadolinium until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity (DLT) OR the dose preceding that at which 2 of 3 or 3 of 6 patients experience DLT.

- Once the MTD is determined, additional patients are treated at that dose level as in phase I.

Patients are followed weekly for 3 months and then monthly for 5 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00089284
Study type Interventional
Source Northwestern University
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date October 28, 2003
Completion date August 20, 2008

See also
  Status Clinical Trial Phase
Completed NCT01448928 - Zevalin Post-marketing Surveillance in Japan
Unknown status NCT01983761 - Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation Phase 1/Phase 2
Recruiting NCT01758042 - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders N/A
Terminated NCT00185679 - Haploid Allogeneic Transplant Using the CliniMACS System Phase 2
Completed NCT01108341 - Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 2
Completed NCT00129090 - Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma Phase 3
Completed NCT01527838 - Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit Phase 1
Completed NCT00923910 - Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Phase 1/Phase 2
Completed NCT00614042 - Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma Phase 1
Completed NCT02071888 - Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors Phase 1
Recruiting NCT04696705 - Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients Early Phase 1
Completed NCT01479387 - Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan N/A
Completed NCT00889798 - Tumor Registry of Lymphatic Neoplasia
Terminated NCT05144347 - Study of XL114 in Subjects With Non-Hodgkin's Lymphoma Phase 1